New CAR T approach minimizes resistance, helps avoid relapse in non-Hodgkin's B-cell lymphoma

Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial found using a bilateral attack achieves a more robust defense and helps avoid relapse.

source https://www.sciencedaily.com/releases/2021/04/210411114051.htm